Register entry
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
- Registered sites
- 0
- Drug products
- 0
- Live patents
- 21
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
21Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| ANORO ELLIPTA | UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE | Jun 2027 |
| ANORO ELLIPTA | UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE | Dec 2027 |
| ANORO ELLIPTA | UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE | Dec 2027 |
| ANORO ELLIPTA | UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE | Nov 2030 |
| TRELEGY ELLIPTA | FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE | Dec 2027 |
| TRELEGY ELLIPTA | FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE | Mar 2030 |
| TRELEGY ELLIPTA | FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE | Sept 2030 |
| TRELEGY ELLIPTA | FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE | Oct 2030 |
| TRELEGY ELLIPTA | FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE | Nov 2030 |
| TRELEGY ELLIPTA | FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE | Apr 2031 |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.